From Davis Polk

Davis Polk advised China Biologic Products, Inc., a NASDAQ-listed company, in connection with its change of domicile from Delaware to the Cayman Islands by its merging with and into China Biologic Products Holdings, Inc., a wholly owned subsidiary of CBPO incorporated in the Cayman Islands, with CBPO Cayman surviving the merger and succeeding to all of China Biologic Products’s interests. Following the completion of the redomicile merger, CBPO Cayman qualifies as a foreign private issuer for U.S. securities law purposes and continues to be listed on NASDAQ under the same symbol.

China Biologic Products is a fully integrated plasma-based biopharmaceutical company in China. Headquartered in Beijing, CBPO manufactures over 20 different dosage forms of plasma products, which are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases.

The Davis Polk corporate team included partner Howard Zhang and counsel Terrence R. O’Donnell. Partner Rachel D. Kleinberg and associate Catherine L. Chu provided tax advice. Counsel Ron M. Aizen and associate Abigail Lane provided executive compensation advice. Zhengxing Xiao was the legal assistant on the transaction. Members of the Davis Polk team are based in the Beijing, Hong Kong, New York and Northern California offices.

SOURCE:  https://www.davispolk.com/news/china-biologic-products-redomicile-delaware-cayman-islands/

IMAGE: Logo